Thymic Carcinoma Clinical Trials

14 recruiting

Frequently Asked Questions

Common questions about Thymic Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

HEARTS Trial for Thoracic Cancers

Non-Small Cell Lung Cancer (Stage III)Esophageal Cancer Stage I-IIIEsophagogastric Cancer Stage I-III+2 more
University of Wisconsin, Madison60 enrolled1 locationNCT07132918
Recruiting
Phase 1

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Stage III Thymoma AJCC v8Stage IIIA Thymoma AJCC v8Stage IIIB Thymoma AJCC v8+4 more
M.D. Anderson Cancer Center37 enrolled1 locationNCT03295227
Recruiting
Phase 2

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

ThymomaThymic Carcinoma
Georgetown University18 enrolled4 locationsNCT06248515
Recruiting
Phase 2

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

ThymomaThymic Carcinoma
The First Affiliated Hospital with Nanjing Medical University20 enrolled1 locationNCT06838910
Recruiting
Phase 2

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Peritoneal MesotheliomaAnaplastic Thyroid CarcinomasCarcinoid Tumor+3 more
Hospices Civils de Lyon154 enrolled15 locationsNCT06790706
Recruiting
Phase 1

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Ovarian CancerCervical CancerLung Cancer+3 more
Chongqing Precision Biotech Co., Ltd90 enrolled1 locationNCT07181720
Recruiting
Phase 2

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Thymic Carcinoma
Dwight Owen30 enrolled3 locationsNCT03463460
Recruiting
Phase 2

Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Jian Chen48 enrolled1 locationNCT06186726
Recruiting

Molecular Analysis and Treatment Options of Thymic Malignancies

Thymic CarcinomaThymic Epithelial TumorThymic Cancer
Shanghai Chest Hospital500 enrolled1 locationNCT05667948
Recruiting
Not Applicable

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

ThymomaThymic Epithelial TumorThymoma and Thymic Carcinoma+1 more
Rongrong Zhou100 enrolled1 locationNCT06692062
Recruiting
Phase 3

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Thymic Carcinoma
Fudan University172 enrolled1 locationNCT06402708
Recruiting

Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

ThymomaThymic CarcinomaThymic Epithelial Tumor+1 more
Erasmus Medical Center1,020 enrolled1 locationNCT06301945
Recruiting
Phase 3

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Thymoma and Thymic Carcinoma
Fudan University1 enrolled1 locationNCT02633514
Recruiting
Phase 2

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas
National Cancer Center, Japan35 enrolled1 locationNCT05832827